CORMEDIX INC. (CRMD) Gross Margin
- Gross margin · 12 months: Value 82.78%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 82.78% | Gross profit / revenue. Period ending 2026-06-30. $382.64M ÷ $462.25M × 100 ≈ 82.78% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 382.64M USD | Gross Profit |
| Revenue | 462.25M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $382.64M | $462.25M | (m) | 82.78% |
| 2026-03-31 | $343.38M | $400.05M | (m) | 85.83% |
| 2025-12-31 | $275.75M | $311.71M | (m) | 88.46% |
| 2025-09-30 | $198.47M | $214.30M | (m) | 92.61% |
| 2025-06-30 | $116.16M | $121.48M | (m) | 95.62% |
| 2025-03-31 | $78.59M | $82.55M | (m) | 95.19% |
| 2024-12-31 | $40.28M | $43.47M | (m) | 92.66% |
| 2024-09-30 | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) |
| 2022-12-31 | $61.67K | $65.41K | (m) | 94.29% |
| 2022-09-30 | $40.77K | $92.10K | (m) | 44.26% |
| 2022-06-30 | $48.34K | $123.37K | (m) | 39.18% |
| 2022-03-31 | $21.18K | $110.31K | (m) | 19.20% |
| 2021-12-31 | $42.00K | $190.94K | (m) | 22.00% |
| 2021-09-30 | $32.09K | $190.25K | (m) | 16.87% |
| 2021-06-30 | $32.27K | $245.18K | (m) | 13.16% |
| 2021-03-31 | $35.77K | $253.44K | (m) | 14.11% |
| 2020-12-31 | $34.38K | $239.23K | (m) | 14.37% |
| 2020-09-30 | $14.56K | $208.29K | (m) | 6.99% |
| 2020-06-30 | $-18.05K | $174.81K | (m) | -10.32% |
| 2020-03-31 | $-1.17K | $193.63K | (m) | -0.60% |
| 2019-12-31 | $-89.97K | $283.27K | (m) | -31.76% |
| 2019-09-30 | $-64.21K | $285.01K | (m) | -22.53% |
| 2019-06-30 | $15.36K | $598.00K | (m) | 2.57% |
| 2019-03-31 | (m) | (m) | (m) | (m) |
| 2018-12-31 | $33.01K | $429.80K | (m) | 7.68% |
| 2018-09-30 | $184.44K | $495.80K | (m) | 37.20% |
| 2018-06-30 | $118.78K | $184.36K | (m) | 64.43% |
| 2018-03-31 | $263.01K | $312.98K | (m) | 84.03% |
| 2017-12-31 | $214.36K | $329.33K | (m) | 65.09% |
| 2017-09-30 | $94.91K | $358.52K | (m) | 26.47% |
| 2017-06-30 | $101.02K | $341.89K | (m) | 29.55% |
| 2017-03-31 | $-187.78K | $222.24K | (m) | -84.49% |
| 2016-12-31 | $-142.57K | $224.10K | (m) | -63.62% |
| 2016-09-30 | $-320.21K | $125.34K | (m) | -255.48% |
| 2016-06-30 | $-320.19K | $116.83K | (m) | -274.06% |
| 2016-03-31 | $-131.34K | $220.29K | (m) | -59.62% |
| 2015-12-31 | $-108.59K | $210.13K | (m) | -51.68% |
| 2015-09-30 | $-156.05K | $272.08K | (m) | -57.35% |
| 2015-06-30 | $-140.83K | $288.58K | (m) | -48.80% |
| 2015-03-31 | $-173.76K | $208.34K | (m) | -83.40% |
| 2014-12-31 | $-256.52K | $189.27K | (m) | -135.53% |
| 2014-09-30 | $-267.41K | $106.37K | (m) | -251.39% |
| 2014-06-30 | $-283.18K | $53.93K | (m) | -525.05% |
| 2014-03-31 | $-268.43K | $14.20K | (m) | -1889.80% |
| 2013-12-31 | $-199.60K | $2.00K | (m) | -9975.21% |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | $0.00 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |